Semi-Annual Consolidated Statement Of Cash Flows

Renascience Inc. - Filing #7253178

Concept 2024-04-01 to
2025-03-31
As at
2025-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
143,763,000 JPY
-256,377,000 JPY
Depreciation
62,000 JPY
1,837,000 JPY
Impairment losses
1,166,000 JPY
4,502,000 JPY
Decrease (increase) in trade receivables
4,400,000 JPY
-4,400,000 JPY
Other, net
14,474,000 JPY
54,000 JPY
Subtotal
-195,331,000 JPY
-228,586,000 JPY
Income taxes paid
-2,095,000 JPY
-1,957,000 JPY
Net cash provided by (used in) operating activities
-176,342,000 JPY
-230,519,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-799,000 JPY
-1,577,000 JPY
Net cash provided by (used in) investing activities
382,147,000 JPY
-1,567,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
9,476,000 JPY
46,500,000 JPY
Repayments of long-term borrowings
-61,658,000 JPY
JPY
Net cash provided by (used in) financing activities
-52,182,000 JPY
46,500,000 JPY
Net increase (decrease) in cash and cash equivalents
153,622,000 JPY
-185,586,000 JPY
Cash and cash equivalents
1,799,816,000 JPY
1,646,193,000 JPY
1,831,780,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.